Eupraxia's strategy for its Eosinophilic Esophagitis (EOE) drug piggybacks on existing procedures. Since EOE patients already undergo endoscopies, the local injection is administered during the same visit. This minimizes the procedural burden on patients and doctors, streamlining adoption and making the hyper-local delivery model feasible and efficient.
Eupraxia's technology is defined by its precision: delivering a stable, flat dose directly into target tissue for up to a year. This hyper-local approach mimics the stability of a continuous IV infusion, aiming to maximize efficacy while minimizing systemic side effects caused by the 'peaks and troughs' of conventional pills or injections.
Eupraxia views its delivery technology as a broad platform beyond one drug. It employs a dual strategy: advancing its own pipeline of proprietary drugs in-house while simultaneously seeking external partnerships for other applications, like cancer therapy. This hybrid model diversifies opportunities and aims to maximize the technology's value across multiple therapeutic areas.